Jasper Therapeutics announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Credit Suisse Securities and William Blair & Company are acting as the active book-running managers for the proposed offering. Oppenheimer & Co. is acting as a passive book-running manager for the proposed offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on JSPR:
- Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock
- Jasper Therapeutics Announces Proposed Public Offering of Common Stock
- Largest borrow rate increases among liquid names
- JSPR Blasts Up on New Cancer Treatment Results
- Jasper Therapeutics to present data for briquilimab at 2023 Tandem Meetings